TAKE ON RMS WITH briumvi® ublituximab-xiiy 150 mg/6 mL injection for IV

BRIUMVI is the only B-cell therapy approved for adults with Relapsing Multiple Sclerosis (RMS) that is given in a

*1-HOUR INFUSION, TWICE PER YEAR.**

TAYLOR, DANTÉ & JULES
Living with RMS and taking BRIUMVI

People featured have been compensated by TG Therapeutics for their time.

*Following the starting dose.

INDICATION

BRIUMVI is a prescription medication used to treat adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.

IMPORTANT SAFETY INFORMATION

WHO SHOULD NOT RECEIVE BRIUMVI?

Do not receive BRIUMVI if you have an active hepatitis B virus (HBV) infection.

Do not receive BRIUMVI if you have had a life-threatening allergic reaction to BRIUMVI. Tell your healthcare provider if you have had an allergic reaction to BRIUMVI or any of its ingredients in the past.

Please see Important Safety Information throughout and on pages 19-21 and full Prescribing Information for BRIUMVI.

WHY CHOOSE BRIUMVI?

The only available 1-hour, twice-per-year* infusion option

95% of all BRIUMVI 1-hour infusions were completed in 1 hour† without interruption in clinical studies

*Following the starting dose.

Proven results in 2 separate, 2-year clinical studies

Reduced relapses by 59% in Study 1 (in Study 2 by 49%) compared to teriflunomide‡

Significantly reduced brain lesions on magnetic resonance imaging (MRI)

Well-studied safety profile

Tested in 2 clinical studies with more than 1,000 people, of whom 545 were given BRIUMVI

Overall infection rates of BRIUMVI & teriflunomide were similar. With BRIUMVI, most were mild to moderate and consisted of upper respiratory tract infection and urinary tract infection

Because safety is so important, BRIUMVI continues to be studied.

†+/-5 minutes.
‡Teriflunomide is the active ingredient in AUBAGIO®. AUBAGIO® is a registered trademark of Sanofi or an affiliate.

IMPORTANT SAFETY INFORMATION

WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT BRIUMVI?

BRIUMVI can cause serious side effects, including:

- **Infusion reactions:** Infusion reactions are one of the most common side effects of BRIUMVI, which can be serious and may require you to be hospitalized. You will be monitored during your infusion and may be monitored after each infusion of BRIUMVI for signs and symptoms of an infusion reaction. Tell your healthcare provider if you get any of these symptoms:
  - fever
  - chills
  - headache
  - flu-like symptoms
  - fast heartbeat
  - hives
  - itchy skin
  - dizziness
  - feeling faint
  - swelling of tongue or throat
  - trouble breathing
  - wheezing
  - nausea
  - abdominal pain
  - throat irritation
  - redness of the face or skin

These infusion reactions can happen over 24 hours after your infusion. It is important that you call your healthcare provider right away if you get any of the signs or symptoms listed above after each infusion. If you get an infusion reaction, your healthcare provider may need to stop or slow down the rate of your infusion.

People featured have been compensated by TG Therapeutics for their time.

HEAR FROM PEOPLE WHO ARE TAKING BRIUMVI

Please see Important Safety Information throughout and on pages 19-21 and full Prescribing Information for BRIUMVI.

briumvi® ublituximab-xiiy 150 mg/6 mL injection for IV

WHAT IS RMS, AND HOW DOES BRIUMVI WORK?

WHAT IS RMS, AND HOW DO B CELLS PLAY A ROLE?

RMS is when a person's own immune system attacks the central nervous system, which includes the brain, spine, and optic nerves. The immune system consists of many cells including B cells. In people with RMS, B cells are believed to contribute to the immune system's attack on myelin—the protective covering around nerves. When myelin is damaged, it can disrupt communication between the brain and the rest of the body.

HOW DOES BRIUMVI WORK?

BRIUMVI is a B-cell therapy designed to specifically target certain B cells and facilitate their removal. Although it is not known exactly how BRIUMVI works, its design is thought to enhance the process by which these specific B cells are removed.

WHAT DOES THIS MEAN FOR PEOPLE LIVING WITH RMS?

Removing certain B cells plays a very important role in the treatment of RMS. Because BRIUMVI is designed to target only certain B cells, the overall immune system is not affected.

Medications that target B cells have been available to treat diseases for more than 25 years and are the most widely prescribed type of medication to treat RMS today.

BRIUMVI was approved by the FDA in 2022.

Please see Important Safety Information throughout and on pages 19-21 and full Prescribing Information for BRIUMVI.

HOW WAS BRIUMVI STUDIED?

BRIUMVI was **well studied in 2 clinical studies**

The clinical studies **each lasted 2 years**

BRIUMVI was tested alongside another treatment (teriflunomide*) in **more than 1,000 people** with RMS

PEOPLE INCLUDED IN THE CLINICAL STUDIES	THIS IS IMPORTANT BECAUSE BRIUMVI WAS STUDIED IN
• 1,089 total people (543 treated with BRIUMVI, 546 treated with teriflunomide)	• A large number of people with RMS
• 18–55 years of age	• A wide age range of people with RMS
• People included in the studies had greater than or equal to 1 relapse within the prior year, or greater than or equal to 2 relapses in the prior 2 years, and/or greater than or equal to 1 gadolinium-enhanced T1 MRI lesion in the prior year	• People who had active disease

*Teriflunomide is the active ingredient in AUBAGIO®. AUBAGIO® is a registered trademark of Sanofi or an affiliate.

IMPORTANT SAFETY INFORMATION

- **Infection:**
  - Infections are a common side effect, and upper respiratory tract infections are one of the most common side effects of BRIUMVI. BRIUMVI increases your risk of getting infections caused by bacteria or viruses that may be life-threatening or cause death. Tell your healthcare provider if you have an infection or have any of the following signs of infection including fever, chills, a cough that does not go away, or painful urination. Your healthcare provider should delay your treatment with BRIUMVI until your infection is gone.
  - **Hepatitis B virus (HBV) reactivation:** Before starting treatment with BRIUMVI, your healthcare provider will do blood tests to check for hepatitis B viral infection. If you have ever had hepatitis B virus infection, the hepatitis B virus may become active again during or after treatment with BRIUMVI. Hepatitis B virus becoming active again (called reactivation) may cause serious liver problems including liver failure or death. Your healthcare provider will monitor you if you are at risk for hepatitis B virus reactivation during treatment and after you stop receiving BRIUMVI.

briumvi® ublituximab-xiiy 150 mg/6 mL injection for IV

BRIUMVI WAS PROVEN TO REDUCE RELAPSES

Results from 543 people treated with BRIUMVI compared to 546 treated with teriflunomide* showed that BRIUMVI was proven superior to teriflunomide at reducing relapses and significantly reducing brain lesions on MRI.

In two separate two-year clinical studies:

STUDY 1

59%

FEWER RELAPSES

with BRIUMVI compared to teriflunomide

Study 1: ARR was 0.076 for BRIUMVI and 0.188 for teriflunomide

STUDY 2

49%

FEWER RELAPSES

with BRIUMVI compared to teriflunomide

Study 2: ARR was 0.091 for BRIUMVI and 0.178 for teriflunomide

ARR; Annualized Relapse Rate=Number of relapses per patient-year (total duration based on the number of follow-up patients when they are exposed to a treatment)

*Teriflunomide is the active ingredient in AUBAGIO®. AUBAGIO® is a registered trademark of Sanofi or an affiliate.

IMPORTANT SAFETY INFORMATION

- **Weakened immune system:** BRIUMVI taken before or after other medicines that weaken the immune system could increase your risk of getting infections.
- **Progressive Multifocal Leukoencephalopathy (PML):** PML is a rare, serious brain infection caused by a virus that may get worse over days or weeks. PML can result in death or severe disability. PML has been reported with BRIUMVI. Tell your healthcare provider right away if you have any new or worsening neurologic signs or symptoms. These symptoms may include weakness on one side of your body, loss of coordination in arms and legs, vision problems, changes in thinking and memory which may lead to confusion, and personality changes.

BRIUMVI SHOWED NEAR-COMPLETE SUPPRESSION OF BRAIN LESIONS

T1 Gd+ lesions suggest inflammation and damage is actively occurring

STUDY 1

97%

FEWER T1 Gd+ LESIONS

with BRIUMVI (0.016) compared to teriflunomide* (0.491) on average per MRI over 2 years

STUDY 2

97%

FEWER T1 Gd+ LESIONS

with BRIUMVI (0.009) compared to teriflunomide (0.250) on average per MRI over 2 years

T2 lesions are areas that indicate long-term impact of MS on the brain. They can either be new lesions or lesions that have gotten bigger.

STUDY 1

92%

FEWER T2 LESIONS

with BRIUMVI (0.213) compared to teriflunomide (2.789) on average per MRI over 2 years

STUDY 2

90%

FEWER T2 LESIONS

with BRIUMVI (0.282) compared to teriflunomide (2.831) on average per MRI over 2 years

*Teriflunomide is the active ingredient in AUBAGIO®. AUBAGIO® is a registered trademark of Sanofi or an affiliate.

Please see Important Safety Information throughout and on pages 19-21 and full Prescribing Information for BRIUMVI.

briumvi® ublituximab-xiiy 150 mg/6 mL injection for IV

MORE PEOPLE TAKING BRIUMVI HAD ZERO RELAPSES

In two separate two-year clinical studies:

STUDY 1

86%

of people taking BRIUMVI had

ZERO RELAPSES

compared to 74% for teriflunomide*

STUDY 2

87%

of people taking BRIUMVI had

ZERO RELAPSES

compared to 72% for teriflunomide

*Teriflunomide is the active ingredient in AUBAGIO®. AUBAGIO® is a registered trademark of Sanofi or an affiliate.

IMPORTANT SAFETY INFORMATION

- **Low immunoglobulins:** BRIUMVI may cause a decrease in some types of antibodies. Your healthcare provider will do blood tests to check your blood immunoglobulin levels.

Before receiving BRIUMVI, tell your healthcare provider about all of your medical conditions, including if you:

- have or think you have an infection.
- take or plan to take medicines that affect your immune system. These medicines may increase your risk of getting an infection.
- have ever had hepatitis B or are a carrier of the hepatitis B virus.
- have a history of liver problems.
- have had a recent vaccination or are scheduled to receive any vaccinations.

Please see Important Safety Information throughout and on pages 19-21 and full Prescribing Information for BRIUMVI.

briumvi® ublituximab-xiiy 150 mg/6 mL injection for IV

MOST PEOPLE EXPERIENCED NO CONFIRMED PROGRESSION OF PHYSICAL DISABILITY*

When taking BRIUMVI or teriflunomide,†

more than 9 out of 10 people

experienced **NO CONFIRMED PROGRESSION OF PHYSICAL DISABILITY**

THERE WAS NO SIGNIFICANT DIFFERENCE

in confirmed disability progression between people who took BRIUMVI (5.2% had confirmed disability progression) and those who took teriflunomide (5.9% had confirmed disability progression).

Physical disability progression was measured at 3 months and combined from both studies.

*Confirmed disease progression was measured at 3 months and was considered progressed if baseline disability score had worsened.
†Teriflunomide is the active ingredient in AUBAGIO®. AUBAGIO® is a registered trademark of Sanofi or an affiliate.

IMPORTANT SAFETY INFORMATION

- **You should receive any required 'live' or 'live-attenuated' vaccines at least 4 weeks before you start treatment with BRIUMVI.** You **should not receive** 'live' or 'live-attenuated' vaccines while you are being treated with BRIUMVI and until your healthcare provider tells you that your immune system is no longer weakened.
- **When possible, you should receive any 'non-live' vaccines at least 2 weeks before you start treatment with BRIUMVI.** If you would like to receive any non-live vaccines while you are being treated with BRIUMVI, talk to your healthcare provider.
- If you have a baby and you received BRIUMVI during your pregnancy, it is important to tell your baby's healthcare provider about receiving BRIUMVI so they can decide when your baby should be vaccinated.

HEAR FROM PEOPLE WHO ARE TAKING BRIUMVI

Please see Important Safety Information throughout and on pages 19-21 and full Prescribing Information for BRIUMVI.

briumvi® ublituximab-xiiy 150 mg/6 mL injection for IV

MOST COMMON SIDE EFFECTS

Side effects that happened in at least 5% of people and were more common with BRIUMVI

SIDE EFFECTS	BRIUMVI n=545	teriflunomide n=548
Infusion reactions	48%	12%
Upper respiratory tract infections	45%	41%
Lower respiratory tract infections	9%	7%
Herpes virus-associated infections	6%	5%
Pain in extremity	6%	4%
Insomnia	6%	3%
Fatigue	5%	4%

These are not all of the possible side effects of BRIUMVI. Talk to your healthcare provider about the possible side effects of BRIUMVI and ask if BRIUMVI may be right for you.

Overall infection rates of BRIUMVI and teriflunomide* were similar

With BRIUMVI, **most were mild to moderate** and consisted of upper respiratory tract infection and urinary tract infection

~90%

of people stayed on treatment throughout both clinical studies

This was similar for people taking BRIUMVI and people taking teriflunomide

*Teriflunomide is the active ingredient in AUBAGIO®. AUBAGIO® is a registered trademark of Sanofi or an affiliate.

IMPORTANT SAFETY INFORMATION

Before receiving BRIUMVI, tell your healthcare provider about all of your medical conditions, including if you:

- are pregnant, think that you might be pregnant, or plan to become pregnant. It is not known if BRIUMVI will harm your unborn baby. You should use birth control (contraception) during treatment with BRIUMVI and for at least 6 months after your last infusion of BRIUMVI. Talk with your healthcare provider about what birth control method is right for you during this time.
- are breastfeeding or plan to breastfeed. It is not known if BRIUMVI passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take BRIUMVI.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

INFUSION REACTIONS WITH BRIUMVI WERE MOSTLY MILD TO MODERATE IN SEVERITY AND WERE LESS COMMON WITH EACH INFUSION



In the studies, people were not given medication to reduce fever prior to Dose 1; however, your healthcare provider may add a medication to reduce fever (e.g., acetaminophen).

LESS THAN 10%

of people experienced infusion reactions after the first dose

97%

of all BRIUMVI infusions were delivered without interruption in clinical trials

A DOSING SCHEDULE THAT MAY HELP PROVIDE MORE TIME FOR YOU



95% of all BRIUMVI 1-hour infusions were completed in 1 hour* without interruption in clinical trials

*±5 minutes.

 Please see Important Safety Information throughout and on pages 19-21 and full Prescribing Information for BRIUMVI.

WHAT TO EXPECT ON A TYPICAL BRIUMVI INFUSION DAY

PRE-INFUSION: 30 - 60 MINUTES

- Pre-infusion medication may be given orally or intravenously (IV) to help reduce possible infusion reactions

DURING INFUSION: 1 HOUR*

*Following the starting dose.

- Infusions (following the starting dose) will typically take 1 hour

POST-INFUSION: FLEXIBLE

- For your first 2 infusions, your healthcare provider will observe you for 1 hour after your infusion is complete
- Post-infusion monitoring is at your healthcare provider's discretion and is not required after your third infusion and beyond (unless you have experienced infusion reactions and/or signs of hypersensitivity with your current or a prior infusion of BRIUMVI)

IMPORTANT SAFETY INFORMATION

WHAT ARE THE POSSIBLE SIDE EFFECTS OF BRIUMVI?

BRIUMVI may cause serious side effects, including:

- See **"What is the most important information I should know about BRIUMVI?"**
- **Liver damage.** BRIUMVI may cause liver damage. Your healthcare provider will do blood tests to check your liver before you start BRIUMVI and while you take BRIUMVI if needed. Tell your healthcare provider right away if you have any symptoms of liver damage, such as:
  - yellowing of the skin and eyes (jaundice)
  - nausea
  - vomiting
  - unusual darkening of the urine
  - feeling tired or weak

briumvi® ublituximab-xiiy 150 mg/6 mL injection for IV

BRIUMVI PATIENT SUPPORT IS HERE TO HELP YOU

briumvi® ublituximab-xiiy 150 mg/6 mL injection for IV

patient support

DEDICATED CASE MANAGER

Your single point of contact to support your treatment journey

INSURANCE SUPPORT

Information to help you understand your insurance coverage and locate a nearby infusion center that accepts your insurance

FINANCIAL ASSISTANCE

Options that may assist you with the cost of BRIUMVI, including the **BRIUMVI Copay Assistance Program** in which eligible patients **may pay as little as $0 copay‡ per BRIUMVI treatment**, and may also help with covering infusion-related costs.

MORE THAN 99%* OF PEOPLE WITH MEDICAL HEALTH INSURANCE, INCLUDING MEDICARE AND MEDICAID, HAVE BRIUMVI COVERAGE†

YOU MAY PAY AS LITTLE AS

$0

COPAY‡ PER BRIUMVI TREATMENT

VISIT **WWW.BRIUMVI.COM** OR CALL **1-833-BRIUMVI** (1-833-274-8684) MON-FRI 8AM TO 8PM ET TO SPEAK WITH A **BRIUMVI PATIENT SUPPORT CASE MANAGER**

*Data provided by MMIT.

†Coverage does not imply superior clinical efficacy or safety. The information provided in this communication is not a guarantee of coverage or payment (partial or full). Actual coverage is determined by each plan administrator in accordance with its respective policy and procedures.

‡For commercially insured patients only. Other eligibility requirements apply. Visit www.briumvicopayterms.com for full terms and conditions.

 Please see Important Safety Information throughout and on pages 19-21 and full Prescribing Information for BRIUMVI.

92% of people reported a positive experience with BRIUMVI Patient Support*

*Source: Primary Market Research. N=1,158 patients who have had at least one infusion of BRIUMVI were surveyed from Jan-May 2025. Respondents were asked to rate the level of support received from the BRIUMVI Patient Support Team during the process of starting therapy; results reflect responses of "excellent," "very good," or "good."

IMPORTANT SAFETY INFORMATION

The most common side effects of BRIUMVI include:

- Infusion reactions, upper and lower respiratory tract infections, herpes infections, extremity pain, insomnia, and fatigue.

briumvi® ublituximab-xiiy 150 mg/6 mL injection for IV

ADDITIONAL SUPPORT AND RESOURCES

A large network of advocacy organizations is ready to help you navigate life with MS. Explore the websites below to access helpful resources, services, and support.

msaa Improving Lives Today!®
Multiple Sclerosis Association of America

MyMSAA.org
1-800-532-7667

CAN DO MULTIPLE SCLEROSIS

CanDo-MS.org
1-800-367-3101

MS National Multiple Sclerosis Society

nationalMSsociety.org
1-800-344-4867

MS views & news

MSViewsandNews.org
1-888-871-1664

ms FOCUS Multiple Sclerosis Foundation

MSFocus.org
1-888-673-6287

REGISTER FOR A **FREE MS EDUCATIONAL EVENT** NEAR YOU

TG Therapeutics is not affiliated with these independent organizations and does not recommend one organization over the other. Please note that the content of these websites is the sole responsibility of the website providers. TG Therapeutics does not control, review, edit, or influence this third-party content in any manner and makes no warranty as to the services offered by any organization listed here. Each organization sets its own eligibility and application process and is independent from TG Therapeutics. TG Therapeutics makes no guarantee a patient will receive any type of assistance or that funding is available. Please contact each organization directly to obtain more information.

IMPORTANT SAFETY INFORMATION

WHO SHOULD NOT RECEIVE BRIUMVI?

Do not receive BRIUMVI if you have an active hepatitis B virus (HBV) infection.

Do not receive BRIUMVI if you have had a life-threatening allergic reaction to BRIUMVI. Tell your healthcare provider if you have had an allergic reaction to BRIUMVI or any of its ingredients in the past.

WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT BRIUMVI?

BRIUMVI can cause serious side effects, including:

- **Infusion reactions:** Infusion reactions are one of the most common side effects of BRIUMVI, which can be serious and may require you to be hospitalized. You will be monitored during your infusion and may be monitored after each infusion of BRIUMVI for signs and symptoms of an infusion reaction. Tell your healthcare provider if you get any of these symptoms:
  - fever
  - chills
  - headache
  - flu-like symptoms
  - fast heartbeat
  - hives
  - itchy skin
  - dizziness
  - feeling faint
  - swelling of tongue or throat
  - trouble breathing
  - wheezing
  - nausea
  - abdominal pain
  - throat irritation
  - redness of the face or skin

These infusion reactions can happen over 24 hours after your infusion. It is important that you call your healthcare provider right away if you get any of the signs or symptoms listed above after each infusion. If you get an infusion reaction, your healthcare provider may need to stop or slow down the rate of your infusion.

- **Infection:**
  - Infections are a common side effect, and upper respiratory tract infections are one of the most common side effects of BRIUMVI. BRIUMVI increases your risk of getting infections caused by bacteria or viruses that may be life-threatening or cause death. Tell your healthcare provider if you have an infection or have any of the following signs of infection including fever, chills, a cough that does not go away, or painful urination. Your healthcare provider should delay your treatment with BRIUMVI until your infection is gone.
  - **Hepatitis B virus (HBV) reactivation:** Before starting treatment with BRIUMVI, your healthcare provider will do blood tests to check for hepatitis B viral infection. If you have ever had hepatitis B virus infection, the hepatitis B virus may become active again during or after treatment with BRIUMVI. Hepatitis B virus becoming active

IMPORTANT SAFETY INFORMATION (CONT.)

again (called reactivation) may cause serious liver problems including liver failure or death. Your healthcare provider will monitor you if you are at risk for hepatitis B virus reactivation during treatment and after you stop receiving BRIUMVI.

- **Weakened immune system:** BRIUMVI taken before or after other medicines that weaken the immune system could increase your risk of getting infections.
- **Progressive Multifocal Leukoencephalopathy (PML):** PML is a rare, serious brain infection caused by a virus that may get worse over days or weeks. PML can result in death or severe disability. PML has been reported with BRIUMVI. Tell your healthcare provider right away if you have any new or worsening neurologic signs or symptoms. These symptoms may include weakness on one side of your body, loss of coordination in arms and legs, vision problems, changes in thinking and memory which may lead to confusion, and personality changes.

- **Low immunoglobulins:** BRIUMVI may cause a decrease in some types of antibodies. Your healthcare provider will do blood tests to check your blood immunoglobulin levels.

Before receiving BRIUMVI, tell your healthcare provider about all of your medical conditions, including if you:

- have or think you have an infection.
- take or plan to take medicines that affect your immune system. These medicines may increase your risk of getting an infection.
- have ever had hepatitis B or are a carrier of the hepatitis B virus.
- have a history of liver problems.
- have had a recent vaccination or are scheduled to receive any vaccinations.
  - **You should receive any required 'live' or 'live-attenuated' vaccines at least 4 weeks before you start treatment with BRIUMVI.** You **should not receive** 'live' or 'live-attenuated' vaccines while you are being treated with BRIUMVI and until your healthcare provider tells you that your immune system is no longer weakened.
  - **When possible, you should receive any 'non-live' vaccines at least 2 weeks before you start treatment with BRIUMVI.** If you would like to receive any non-live vaccines while you are being treated with BRIUMVI, talk to your healthcare provider.
  - If you have a baby and you received BRIUMVI during your pregnancy, it is important to tell your baby's healthcare provider about receiving BRIUMVI so they can decide when your baby should be vaccinated.
- are pregnant, think that you might be pregnant, or plan to become pregnant. It is not known if BRIUMVI will harm your unborn baby. You should use birth control (contraception) during treatment with BRIUMVI and for at least 6 months after your last infusion of BRIUMVI. Talk with your healthcare provider about what birth control method is right for you during this time.

IMPORTANT SAFETY INFORMATION (CONT.)

- are breastfeeding or plan to breastfeed. It is not known if BRIUMVI passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take BRIUMVI.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

WHAT ARE THE POSSIBLE SIDE EFFECTS OF BRIUMVI?

BRIUMVI may cause serious side effects, including:

- See **"What is the most important information I should know about BRIUMVI?"**
- **Liver damage.** BRIUMVI may cause liver damage. Your healthcare provider will do blood tests to check your liver before you start BRIUMVI and while you take BRIUMVI if needed. Tell your healthcare provider right away if you have any symptoms of liver damage, such as:
  - yellowing of the skin and eyes (jaundice)
  - nausea
  - vomiting
  - unusual darkening of the urine
  - feeling tired or weak

The most common side effects of BRIUMVI include:

- Infusion reactions, upper and lower respiratory tract infections, herpes infections, extremity pain, insomnia, and fatigue.

These are not all the possible side effects of BRIUMVI. Call your doctor for medical advice about side effects. You may report side effects to FDA at **1-800-FDA-1088**. You may also report side effects to TG Therapeutics at **1-877-TGTXINC (1-877-848-9462)**.

For more information, go to **www.briumvi.com** or call **1-833-BRIUMVI (1-833-274-8684)**.

ASK YOUR HEALTHCARE PROVIDER IF BRIUMVI IS RIGHT FOR YOU



BRIUMVI IS THE ONLY B-CELL THERAPY APPROVED FOR ADULTS WITH RMS THAT IS GIVEN IN A **1-HOUR INFUSION, TWICE PER YEAR***

*FOLLOWING THE STARTING DOSE.

95% OF ALL BRIUMVI 1-HOUR INFUSIONS WERE **COMPLETED IN 1 HOUR† WITHOUT INTERRUPTION** IN CLINICAL STUDIES

†+/- 5 MINUTES.

BRIUMVI WAS **PROVEN EFFECTIVE** AND HAS A **WELL-STUDIED SAFETY PROFILE** IN 2 CLINICAL STUDIES

@briumvi_ublituximab_xiiy

@BRIUMVI® (ublituximab-xiiy)

@BRIUMVI® (ublituximab-xiiy)

www.BRIUMVI.com

STAY INFORMED:
JOIN THE THOUSANDS TAKING ON RMS WITH BRIUMVI.
SIGN UP TODAY!

Please see Important Safety Information throughout and on pages 19-21 and full Prescribing Information for BRIUMVI.